TB-500 (Thymosin Beta-4)
TB-500 is sold as a healing peptide, and the first thing to understand is that "TB-500" and the peptide in the actual research trials are usually not the same molecule. The trials used full-length thymosin beta-4 (Tβ4), a 43-amino-acid protein the body makes in nearly every tissue. Most vials sold as "TB-500" contain a synthetic fragment — the acetylated seven-amino-acid piece (Ac-LKKTETQ) that holds the actin-binding activity — chosen because it's cheaper to make. That single fact reshapes how you should read every efficacy and safety claim below. This page covers what Tβ4 actually does, what has and hasn't been shown in humans, the fragment problem, real dosing and reconstitution, the cancer question that defines its risk, its ban in sport, and where it sits in a disc-recovery stack. Zero prior knowledge assumed.
What it actually is
Thymosin beta-4 is the body's main G-actin-sequestering peptide. Actin is the protein a cell uses to build and tear down its internal skeleton; controlling that is how a cell changes shape and crawls. Tβ4 binds actin monomers one-to-one and regulates that machinery, which is why it shows up wherever tissue is rebuilding — wounds, healing heart, migrating repair cells.
TB-500 is not thymosin beta-4 — read this before anything else
The distinction is routinely buried by vendors and it is central:
- Thymosin beta-4 (Tβ4): the full 43-amino-acid protein used in every legitimate human and animal trial (IV cardiac, RGN-259 eye drops, wound studies).
- "TB-500": a marketed synthetic fragment, the acetylated heptapeptide Ac-LKKTETQ (residues 17-23, ~889 Da), sold as a stable, cheaper stand-in. It reproduces the actin-binding activity but is not the molecule trialed clinically.
To make it worse, full-length Tβ4 is also cleaved in the body to a different active fragment (Ac-SDKP), and some products sold as "TB-500" actually contain that instead. So "TB-500" is not even one consistent substance across vendors — you often cannot know which molecule you received. Efficacy and safety data for full Tβ4 cannot simply be assumed to transfer to whatever is in the vial.
One short motif does the healing
The repair-relevant part of Tβ4 is that seven-amino-acid actin-binding motif, and the same motif drives angiogenesis and endothelial cell migration — the growth of new blood vessels.
That matters for a disc because tendon, ligament, and disc are poorly vascularized, and blood supply is the rate-limiter on healing them. A repair mechanism that is intrinsically pro-angiogenic is aimed straight at that bottleneck. On paper.
The human record: one clear win, several honest misses
In animal wound models the effect is clean — topical or systemic Tβ4 sped skin regrowth by 42-61% while adding collagen and vessels.
In humans, full Tβ4 went into proper randomized, placebo-controlled trials for chronic wounds (pressure ulcers, venous stasis ulcers). Honest result: safe and well tolerated, but the primary healing endpoints did not reach statistical significance.
The one indication where human data turned clearly positive is the eye. The ophthalmic formulation RGN-259 significantly improved dry-eye signs and symptoms versus placebo in Phase 2 trials.
So the truthful summary is narrow: one positive human indication (dry eye), wound trials that were safe but unproven, and — for tendon, ligament, muscle, and disc — no confirmatory human trial at all.
Heart, stroke, ligament: the preclinical case
The animal repair record is broad and consistent with the mechanism. After a heart attack, Tβ4 given locally and systemically shrank infarct size and improved function via cell-survival pathways (ILK/Akt) with less scarring — and the systemic result matters, because it shows the peptide reaches a distant injury and acts there.
In a rat embolic stroke it improved neurological outcome through remyelination and axonal remodeling.
And in the tissue class closest to a disc stack, it improved ligament healing (rat MCL) both structurally and mechanically.
How people dose and reconstitute it
No human dose-finding trial of the TB-500 fragment exists, so every protocol is practitioner/anecdotal — folklore, not medicine.
- Dose (anecdotal): a loading phase around 4-6 mg per week (split into two injections) for 4-6 weeks, then maintenance ~2-2.5 mg weekly or every other week, total cycle 8-12 weeks, then time off. These mg-scale numbers apply to the fragment; the full-Tβ4 trials dosed completely differently (e.g. micrograms/kg IV in the cardiac trial), so the anecdotal mg figures have no validated basis.
- Route: subcutaneous or intramuscular injection; no oral activity (it's digested).
- Reconstitution: lyophilized powder mixed with bacteriostatic water; swab the stopper, run diluent down the wall, swirl — don't shake. Refrigerate at 2-8 °C, protect from light, avoid freeze-thaw; commonly cited stable ~28 days once mixed. These are vendor guidelines, not pharmacopeial stability data.
The cancer question — this is the real safety story
Here the angiogenesis mechanism cuts against it. Tβ4 is overexpressed in many solid tumors, and there it is associated with more migration, metastasis, and blood-vessel growth.
The literature is genuinely two-directional — in multiple myeloma Tβ4 behaves as a tumor suppressor — but the practical point stands: the same pro-angiogenic, pro-migration activity that plausibly helps a healing tendon is the activity implicated in tumor progression.
The sane default that falls out of this: treat active malignancy or a significant cancer history as a contraindication. This is a sharper safety concern than BPC-157 carries, where the tumor evidence actually points the other way.
Banned in sport, and heavily policed
If you compete in anything drug-tested, stop here. TB-500/Tβ4 is on the WADA Prohibited List, banned at all times under the peptide-hormones/growth-factors section via its catch-all language.
It's not theoretical enforcement: it became infamous in the Australian NRL supplements scandal, it's a well-known horse-racing dope, and athletes have taken multi-year bans for it.
What people report
The anecdote layer runs almost entirely through BPC-157 + TB-500 stacks, and it's specifically the tendon-and-back crowd — torn biceps and forearm tendons, chronic Achilles and patellar tendinitis, and sacral/back pain.
Uncontrolled, confounded, self-selected, and — given the fragment problem — often not even a known molecule. Real people, not real evidence.
Where it fits for the spine
In the stack, TB-500 is the systemic repair signal that complements BPC-157's more locally-studied effects; both push angiogenesis and cell migration into the poorly-vascularized tissue a disc is made of, and Tβ4's anti-fibrotic bias (repair over scar) is the appealing part. But it is theory stacked on an identity problem: no one has tested TB-500 against a human disc, the fragment may not match the trialed molecule, and the cancer-mechanism caution is real. It belongs in the framework in the disc-stack, herniated-disc, and degenerative-disc-disease pages — with those caveats attached, not stripped off.
Proven, unproven, and the catch
Proven: Tβ4 regulates actin and drives angiogenesis; it heals animal wounds and improves human dry eye in an RCT; it's anti-fibrotic and reaches distant injuries systemically in animals. Unproven: that it heals tendon, ligament, or disc in people. The catch specific to this compound: the product sold as "TB-500" is usually a fragment, not the trialed protein, so even the transferable evidence may not apply to what's in the syringe. And the angiogenesis that helps healing is the same mechanism that argues against use in cancer.
Not medical advice. TB-500 is sold for research use only, is not an approved treatment, and is banned in tested sport. Nothing here is a dosing or treatment recommendation.
Key evidence
Model review51 contributions · 5 modelsExpand the recursive review layer
/api/articles/tb-500/contributionsAsk this article · 8 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.